IDKmonitor Vedolizumab Free Anti-drug Antibody ELISA 96 Wells


Vedolizumab is a recombinant protein that has the potential to induce humoral immune responses and lead to anti-drug antibody formation; a major cause of loss of response.

These Anti-drug antibodies can bind and neutralise the drug accelerating its clearance and reducing its efficacy.  Monitoring the efficacy of Vedolizumab may help clinicians schedule a successful individualised treatment strategy for their patients.

Free Anti-Vedolizumab Antibody ELISA

Free anti-drug antibody ELISAs (“drug sensitive assays”) enable the detection of anti-drug antibodies that are not bound to other proteins or therapeutic drugs.

IDKmonitor® Vedolizumab Free Anti-drug Antibody ELISA is a quantitative assay that detects human antibodies against Vedolizumab in EDTA plasma and serum samples by capturing the anti-Vedolizumab antibodies on the microplate.


  • Detects free anti-Vedolizumab Antibodies in Serum and Plasma

  • Microplate coated with highly specific Vedolizumab fragments

  • 1 calibrator, 2 controls

  • Capacity for 45 samples in duplicate

  • Assay time 130 minutes

  • Automatable on ELISA automates (e.g. Dynex D2)


  • Supports the investigation of primary non response and loss of response to Vedolizumab

  • Drug sensitive assay only detects free anti-Vedolizumab antibodies (those not bound to Vedolizumab)

  • May help predict long term outcome of disease in patients with sub-therapeutic Vedolizumab levels

  • UK publications and evidence base

  • Available via reference laboratories in UK

  • Applicable to Gastroenterology